NSCLC
Conditions
Keywords
Malignant Pleural Effusion
Brief summary
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural effusion. Eligible patients need confirmed measurable lesions; intravenous cohort requires EGFR/ROS1/ALK negativity and disease progression after PD-(L)1 inhibitor treatment, while intrapleural cohort accepts targeted therapy-resistant patients with ≥500ml pleural effusion, and the treatment's safety, efficacy and immune microenvironment changes will be evaluated.
Interventions
DRUGNK510
Intravenous infusion
DRUGTislelizumab，atezolizumab or sugemalimab
Administer according to the instructions
DRUGsystemic therapy as selected by the investigator
Administer according to the instructions
Sponsors
Base Therapeutics (Shanghai) Co., Ltd.
Jinling Hospital, China
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Dose escalation study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years, male or female. * For dose expansion group (Group A/B/C): A. EGFR mutation-negative, ROS1-negative, and ALK-negative; unresectable and non-radiotherapeutic stage III or IV, locally advanced, recurrent or metastatic NSCLC. B. Disease progression after ≥4 courses of PD-(L)1 blockade ± chemotherapy. * For pleural perfusion group (Group D1/D2): Advanced NSCLC with malignant pleural effusion ≥500ml (confirmed by B-ultrasound or CT); patients with driver gene-positive and resistant to targeted therapy are acceptable. * At least one CT or MRI measurable lesion according to RECIST v1.1. * ECOG performance status 0-2. * Expected survival ≥3 months. * All toxicities from previous anti-tumor therapy (except alopecia and fatigue) resolved to grade 1 (CTCAE v5.0) or baseline; subjects with long-term sequelae from previous therapy (e.g., neuropathy after platinum-based therapy) are acceptable. * Fertile females must be non-lactating and have a negative serum pregnancy test within 1 week before enrollment; all subjects (male or female) must agree to use contraception from signing informed consent until 6 months after the last NK510 infusion. * Able to comply with the study protocol and follow-up procedures. * Voluntarily sign the informed consent form.
Exclusion criteria
* Symptomatic central nervous system (CNS) metastasis and/or carcinomatous meningitis. * Active, known or suspected autoimmune diseases (excluding type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, skin diseases not requiring systemic treatment \[e.g., vitiligo, psoriasis, alopecia\] or diseases not expected to recur without external triggers). * History of severe cardiovascular and cerebrovascular diseases, including but not limited to: severe cardiac arrhythmia or conduction abnormalities requiring clinical intervention (e.g., ventricular arrhythmia, grade III atrioventricular block); QTc interval \>480 ms on 12-lead ECG at rest; acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grade ≥3 cardiovascular and cerebrovascular events within 6 months before enrollment; NYHA cardiac function class ≥II or left ventricular ejection fraction (LVEF) \<50%; clinically uncontrolled hypertension. * Blood transfusion, erythropoietin, granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor treatment within 2 weeks before enrollment. * Systemic treatment with corticosteroids (prednisone \>10 mg/day or equivalent) or other immunosuppressive/immunomodulatory drugs (e.g., thymosin, interleukin-2, interferon) within 2 weeks before enrollment; inhalation or topical corticosteroids are allowed in subjects without active autoimmune diseases. * Known allergy or intolerance to PD-(L)1 blockade. * Meeting any of the following laboratory criteria: 1. Hematology: Neutrophils \<1.5×10⁹/L; Platelets \<75×10⁹/L; Hemoglobin \<90 g/L. 2. Liver function: ALT \>3×ULN (≥5×ULN in patients with liver metastasis); AST \>3×ULN (≥5×ULN in patients with liver metastasis); TBIL \>1.5×ULN or \>2.5×ULN (3.0 mg/dL) in patients with Gilbert syndrome. 3. Renal function: Serum creatinine \>1.5×ULN or creatinine clearance \<50 mL/min. * Any other severe or uncontrollable medical diseases, active infections, physical examination abnormalities, laboratory test abnormalities, mental status changes or mental illnesses that increase subject risk or affect study results (assessed by investigator).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting toxicity and incidence of adverse events | 6 weeks | To evaluate DLT and the incidence of AEs associated with NK510 treatment |
| Objective Response Rate | 6 weeks | For intravenous groups: Proportion of subjects achieving CR and PR according to RECIST v1.1 after first NK510 administration; For pleural perfusion groups: Proportion of subjects achieving CR and PR according to WHO criteria after first NK510 intrapleural perfusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival | From the date of the first dose of NK510 until disease progression, death, or a maximum of 24 months after the first dose, whichever occurs first. | Time from first NK510 administration to disease progression or death. |
| Puncture-Free Survival | From the date of the last treatment puncture to the date of the next puncture drainage, or up to a maximum of 24 months after the last treatment puncture, whichever occurs first. | Time from last treatment puncture to next puncture drainage (for pleural perfusion groups). |
| Duration of Response | From the date of first documentation of objective response to disease progression, death, or a maximum of 24 months after the date of first response, whichever occurs first. | Time from achievement of response to disease progression. |
| Disease Control Rate | From baseline tumor assessment up to the earliest of disease progression，or a maximum of 24 months after baseline. | Proportion of subjects achieving CR, PR or SD based on baseline tumor assessment. |
| Overall Survival | From the date of screening enrollment to death, or a maximum of 24 months after screening enrollment, whichever occurs first. | Time from screening enrollment to death. |
| Health-Related Quality of Life | At screening, every 6 weeks during treatment, at study completion, or up to a maximum of 24 months after the first dose, whichever occurs first. | Assessed by EORTC QLQ-C30 (V3.0) scale. |
Countries
China
Contacts
CONTACTJun Yan, PhD
CONTACTTangfeng Lv
PRINCIPAL_INVESTIGATORTangfeng Lv, PhD
Jinling hospital, Nanjing, China
Outcome results
None listed